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Abstract  
Introduction: Since December 2019, an outbreak of Covid-19 has caused growing concern in multiple 
countries. Researchers around the world are working to find a treatment or a vaccine for Covid-19 and 
different treatment approaches have been tested in this regard. 
Objective: This study was designed and conducted to assess the possible efficacy of Interferon beta-1a as a 
safe and efficient candidate for Covid-19 treatment. 
Methods: This is an investigator-initiated, open-label, single-arm clinical trial. Twenty patients with suspected 
Covid-19, who were admitted to Sina hospital in Tehran, Iran, with moderate to severe symptoms, from 6 to 
10 March, 2020, were enrolled. Patients were treated with antiviral and hydroxychloroquine combination 
therapy, along with subcutaneous Interferon beta-1a for 5 consecutive days. Baseline characteristics and 
findings during the course of admission and 5 days after discharge were recorded for all the patients.  
Results: In total, 20 patients with suspected Covid-19 were included in this study, 12 (60%) of which were 
male. The median (Interquartile (IQ) range) of patients’ age was 55.5 (43-63.5). The most common symptom 
of the patients at onset of disease was fever. The median (IQ range) of duration of hospital stay was 5.0 (3-6) 
days. Only 2 cases were admitted to ICU. At the time of follow-up, 15 (94%) patients reported that they 
generally felt good and had oral tolerance, 1 patient had suffered from dyspnea, 5 patients had suffered from 
cough, none of them had experienced fever and no case of re-admission or death was reported after discharge. 
Conclusions: Results of the current study are in favor of using Interferon beta-1a in addition to recommended 
antiviral treatment in Covid-19 patients. 
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INTRODUCTION
In December 2019, some cases of pneumonia were 
reported in Wuhan, China, which were different 
from known pneumonia. The virus causing this 
disease was later named Severe Acute Respiratory 
Syndrome Coronavirus 2 (SARS-CoV-2) (1, 2). The 
disease caused by this virus is rapidly spreading 
around the world and according to the World 
Health Organization (WHO) report, more than 4 
million cases had been confirmed by 15 May 2020 
(3) and therefore, it has been announced as a public 
health emergency and a pandemic (3).  
The first case of Covid-19 in Iran has been detected 
on 19th of February, 2020 and after that we faced 
huge outbreak of this virus around the country. 
Until 15 May, 2020, Iran has had about 117,000 
confirmed cases of Covid-19 and has ranked 
second in Asia after China. Researchers around the 
world are working to find a treatment or a vaccine 
for Covid-19 and different treatment approaches 
have been tested in this regard (4-6). SARS-CoV-2 
is genetically related to the previously known 
coronavirus, SARS-CoV, with more than 79% 
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similarity between their sequences, which may 
lead to the effectiveness of SARS-CoV medicines in 
treatment of SARS-CoV-2 (4, 7). 
Interferons have been evaluated in several studies 
in this regard and results indicate its efficacy in 
SARS-CoV-infected patients (8-11). In the study by 
Cinatl et al., it was shown that Interferons inhibit 
SARS-CoV replication in vitro and improve efficacy 
of antiviral drugs; moreover, this analysis indicated 
more potency for Interferon-beta compared to 
Interferon-alpha or gamma (8). This introduces 
this medicine as a candidate in combination with 
other antiviral drugs in the treatment of SARS  or 
Covid-19 (8). Cell culture and animal studies also 
confirmed that Interferon (alpha/beta) should be 
administered as high-dose to be effective against 
SARS-CoV and MERS-CoV and this should be 
considered for patients (12). Furthermore, studies 
recommended that Interferon therapy should be 
initiated as early as possible when the disease is 
diagnosed, which can be due to its antiviral 
function and prophylaxis in non-infected cells (11, 
13). As a result, Interferons, which are approved 
medications against several viral and autoimmune 
diseases, may offer the possibility of both 
prevention and treatment of Covid-19 in 
combination with antiviral drugs (14, 15). This 
study was designed and conducted to assess the 
possible efficacy of Interferon beta-1a as a safe and 
efficient candidate for Covid-19 treatment. 
Methods 
Study design and patient enrollment  
This is an investigator-initiated, open-label, single-
arm trial focusing on the clinical data of confirmed 
cases of Covid-19 in Sina Hospital in Tehran city, 
Iran, during 6-10 March, 2020. Using non-
random sampling methods, 20 eligible patients 
were enrolled after signing the consent form. 
Since the outbreak of Covid-19, specific hospitals 
were designated as main centers for Covid-19 
patients. All suspected patients were transferred to 
these hospitals for confirmation and isolation. 
Considering the hospital-approved protocol, and 
due to delay in receiving the results of real time 
polymerase chain reaction (PCR) tests for 
confirmation of the disease and the patients were 
admitted based on clinical judgment and chest 
computed tomography (CT) scan findings. We sent 
a sample for PCR, but did not delay the treatment 
for receiving the positive result. To cope with the 
shortage of hospital beds, Sina Hospital did not 
admit patients who had O2 saturation >93%, and 
stable vital signs and no underlying disease 
(diabetes mellitus, hypertension, ischemic heart 
disease, malignancy, asthma, use of corticosteroids 
and etc.), and had "mild" findings on their chest CT 
scan. A radiology resident and an attending 
emergency physician evaluated the chest CT scan 
of all suspected patients (16). To determine 
involvement severity on chest CT scan, each of the 
five lung lobes were assessed and amount of 
involved area in each lobe was scored as 0 for none, 
1 for 1-25%, 2 for 26-50%, 3 for 51-75% and 4 for 
76-100%. An overall lung severity score was 
calculated by summing the five lobe scores (ranged 
between 0-20) (17). We defined mild involvement 
as a score of 5 or less, moderate involvement as a 
score of 6-14 and severe involvement as a score of 
15-20. Pregnant patients, those who were breast-
feeding and those who had known allergy to 
Interferon beta, were excluded. The trial was 
approved by ethical committee of Tehran 
University of Medical Sciences 
(IR.TUMS.VCR.REC.1399.026) and registered in 
Iranian Registry of Clinical Trials 
(IRCT20150914024017N1). 
Treatment regimen 
Routine treatment protocol for Covid-19 patients 
in Sina Hospital was a combination of medications 
based on available evidence at the time and clinical 
judgment of the treating physician. The treatment 
protocols included hydroxychloroquine (200 mg 
twice daily), Lopinavir/Ritonavir (200/50mg four 
times daily), Oseltamivir (75 mg, twice daily) and 
Ribavirin (1200 mg twice daily) during 
hospitalization. We added ReciGen (Interferon beta 
1-a, CinnaGen Co., nationally approved biosimilar 
of Rebif®) subcutaneous administration (44µg 
every day until discharge or until 5th day of 
admission, either one that came first) to the routine 
treatment protocols of the patients. 
Clinical laboratory measurements 
Routine lab tests including white blood cell (WBC) 
count, lymphocyte count, sodium, potassium, 
creatinine, lactate dehydrogenase and C-reactive 
protein (CRP) for each patient were performed on 
the day of admission. Oxygen was administered for 
hypoxic patients using either nasal cannula or 
facial mask, and cardiac monitoring was performed 
for all patients. The patients' vital signs and O2 
saturation were recorded at the time of admission 
and during the hospital stay until discharge. The 
need for intensive care unit (ICU) admission and 
intubation was evaluated by the treating physician 
daily or whenever the patient’s situation 
exacerbated. Patients suspected of SARS-CoV-2 
were discharged based on the hospital protocol, 
once they became afebrile with normal O2 
saturation in room air, and without dyspnea.  All of 
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the patients were followed for 5 days after being 
discharged from the hospital via telephone calls 
and all conditions or adverse events were 
recorded. 
Statistical analysis 
In this study, continuous variables were depicted 
as either mean ± standard deviation (SD) or median 
with interquartile (IQ) range. Some of the variables 
were categorized and data were also presented for 
each category. All analyses were done using free R-
3.6.1 version of RStudio software. 
RESULTS 
In total, 20 patients with suspected Covid-19, were 
included in this study, 12 (60%) of which were 
male. The median (IQ) of patients’ age was 55.5 
(43-63.5) years. The youngest patient was 26 years 
old and the oldest was 73 years old. The baseline 
characteristics of the studied patients are shown in 
table 1. Based on the findings, 15 patients had at 
least one known underlying disease and 5 patients 
(25%) did not have any. It is obvious that all of the 
patients had abnormal chest CT scan on the day of 
admission.  
Vital signs of the studied patients during the 5-day 
treatment period are reported in table 2. The most 
common symptom of the patients at onset of 
disease was fever. Also, 10 (50%) patients had O2 
saturation less than 93% on the day of admission.  
Serial laboratory findings of the patients are 
reported in table 3; On the first day of 
hospitalization, white blood cell count was less 
than 4×103/µl (leucopenia) in 3 (15%) patients, 
between 4-10×103/µL in16 patients, and more 
than 10×103/µl in one patient. Furthermore, 
lymphocyte count of 8 (40%) patients, hemoglobin 
level of 2 patients (10%), and platelet count of 6 
(30%) patients was outside the normal range on 
the day of admission.  
 The frequency of applying each treatment 
regimen, findings during hospital stay, and length 
of hospital stay of the studied patients are reported 
in table 4. Of the 20 patients, 2 were admitted to 
ICU, one of them was later discharged and one of 
them died after 45 days of hospitalization. The 
mean (±SD) of hospital stay was 6.75 (±9.2) days. 
All of the patients received at least one antiviral 
treatment in their treatment combination regimen. 
Positive PCR results for Covid-19 were reported in 
only 6 (30%) patients.  
We screened the patients for adverse events during 
hospitalization and no case of adverse events were 
reported. Fever, dyspnea, and oral tolerance were 
recorded, separately, as clinical features of Covid-
19. Five days after discharge of the patients from 
the hospital, the patients were followed up by 
telephone call to record their data and 16 patients 
were reached after calling twice. One of the 
patients had died after being discharged and was 
Table 1: Baseline characteristics of studied patients (n=20) 
Characteristics n (%) 
Age (years) 
≤ 40 3 (15.0) 
41 – 60 9 (45.0) 
≥ 61 8 (40.0) 
Sex 
Male 12 (60.0) 
Female 8 (40.0) 
Medical history 
Hypertension 5 (25.0) 
Diabetes mellitus 6 (30.0) 
Chronic obstructive pulmonary disease 1 (5.0) 
Cardiovascular disease 2 (10.0) 
Immunosuppressant use in past 2 weeks 2 (10.0) 
Corticosteroid use in past 2 weeks 2 (10.0) 
Chronic kidney disease 1 (5.0) 
None 5 (25.0) 
Number of consolidated lobes in chest CT scan 
3 1 (5.0) 
6-7 3 (15.0) 
8-9 4 (20.0) 
10-11 3 (15.0) 
12-13 2 (10.0) 
Imaging not available 7 (35.0) 
 
 
 
Table 2: Vital signs of the studied patients during the 5-day treatment period 
Variable 
Day 1 
(n=20) 
Day 2 
(n=20) 
Day 3 
(n=18) 
Day 4 
(n=13) 
Day 5 
(n=11) 
Temperature; mean±SD (°C) 37.5±0.69 37.3±0.82 37.3±0.67 37.8±0.98 37.2±0.65 
< 37.3 8 (40.0) 11 (55.0) 11 (61.1) 5 (38.5) 7 (63.7) 
 37.3 – 38.0  8 (40.0) 7 (35.0) 5 (27.8) 3 (23.7) 3 (27.3) 
38.01 – 39.0  4 (20.0) 1 (5.0) 1 (5.6) 3 (23.7) 1 (9.1) 
> 39.0 0 (0.0) 1 (5.0) 1 (5.6) 2 (15.4) 0 (0.0) 
Respiratory rate; mean±SD (/min) 25.1±7.9 21.2±5.7 21.6±7.3 23.7±5.8 25.6±5.9 
Respiratory rate >24 breaths per min 7 (35.0) 5 (25.0) 5 (27.8) 4 (30.8) 4 (36.4) 
Pulse rate; mean±SD (/min) 86.9±13.7 81.4±9.8 76.9±9.2 79.4±9.1 74.8±6.7 
Systolic Blood Pressure; mean±SD (mmHg) 120.9±14.2 121.7±17.4 120.6±13.5 118.7±10.6 118.4±10.0 
Diastolic Blood Pressure; mean±SD (mmHg) 73.1±10.1 77.9±12.8 71.6±10.5 73.8±9.6 72.3±11.3 
O2 Saturation; mean±SD (%) 93.0±5.4 93.9±5.3 95.3±3.6 92.4±4.6 90.3±4.7 
Values are presented as mean±SD, or frequency (percent). 
ADVANCED JOURNAL OF EMERGENCY MEDICINE. 2020;4(2s):e51 Payandemehr et al 
   
 
4 Copyright © 2020 Tehran University of Medical Sciences  
This open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 License (CC BY-NC 4.0). 
 
not considered for follow-up. In this step, 15 
patients reported that they generally felt good, all 
of them had oral tolerance, 1 of the patients had 
suffered from dyspnea, 5 of the patients had 
suffered from cough, none of them had experienced 
fever and no case of re-admission or death was 
reported after discharge.  
DISCUSSION 
All of the patients in the current study were treated 
with Interferon beta-1a plus different combination 
treatments including antiviral drugs. Interferon 
beta-1a has been used in high dose on the first day 
of hospital admission. This dosage of Interferon 
beta-1a, 44µg, has been approved for treatment of 
multiple sclerosis two decades ago and using high 
dose of Interferon beta-1a, as a natural antiviral  
protein, has been reported to be safe in other 
indications like hepatitis (18). After the first 
administration of the drugs, patients’ clinical 
features improved and only one case of death was 
reported after 45 days of hospitalization. 
Moreover, other outcomes of patients were 
satisfactory and the mean duration of hospital stay 
for all of the patients was 6.75 days.  
Since Covid-19 was announcement to be a 
pandemic, finding the appropriate or effective 
treatment for this disease is crucial and various 
available antiviral agents in combination with 
other drugs are being evaluated. Based on previous 
data about the efficacy of Interferon beta against 
SARS-CoV (8, 9, 12, 14) and the similarity of this 
Table 3: Serial laboratory findings of the studied patients 
Characteristics Day 1 (n=20) Day 2 (n=13) Day 3 (n=7) 
White blood cell count (×103/µl) 5.9 (4.6 – 7.2) 4.3 (4.1 – 6.1) 4.2 (3.7 – 5.9) 
< 4 3 (15.0) 2 (15.4) 3 (42.9) 
4 – 10.5 16 (80.0) 11 (84.6) 4 (57.1) 
> 10.5 1 (5.0) 0 (0.0) 0 (0.0) 
Lymphocyte count (%) 20.7 (17.3 - 32.0) 25.3 (18.6 – 30.7) 25.3 (22.5 – 34.2) 
<20 8 (40.0) 4 (30.8) 1 (14.3) 
20-45 12 (60.0) 8 (61.5) 6 (85.7) 
>45 0 (0.0) 1 (7.7) 0 (0.0) 
Hemoglobin (mg/dl) 14.3 (13.0 – 14.8) 13.1 (11.5 – 13.9) 12.4 (8.5 – 12.8) 
Platelet count (×103/µl) 204.5 (129 – 264.3) 212.0 (161 – 266) 221.0 (159 – 317) 
< 150 6 (30.0) 2 (15.4) 1 (14.3) 
≥ 150 14 (70.0) 11 (84.6) 6 (85.7) 
Sodium (meq/L) 136 (131.0 - 137.9) - - 
Potassium (meq/L) 4.1 (3.9 – 4.5) - - 
Creatinine (mg/dl) 1.0 (0.9 – 1.3) - - 
< 0.7 0 (0.0) - - 
0.7 – 1.4 16 (80.0) - - 
> 1.4 4 (20.0) - - 
Lactate dehydrogenase 577 (469.0 – 963.5) - - 
C-reactive protein 60.2 (32.5 – 122.6) - - 
Analysis was based on the available data, missing data were not considered. Values were presented as median (interquartile, IQ), or 
frequency (percent) 
 
Table 4: Frequency of applying each treatment regimen, findings during hospital stay, and length of hospital stay of the studied patients 
Category Value 
Treatment 
Hydroxychloroquine-Oseltamivir-Lopinavir/Ritonavir-ReciGen (Interferon beta-1a) 10 (50.0) 
Hydroxychloroquine-Oseltamivir-Lopinavir/Ritonavir-Ribavirin-ReciGen (Interferon beta-1a) 8 (40.0) 
Oseltamivir-Lopinavir/Ritonavir-Ribavirin 1 (5.0) 
Oseltamivir – Lopinavir/Ritonavir 1 (5.0) 
Patients who received Vancomycin 7 (35.0) 
In-hospital findings 
Number of patients who required admission in ICU 2 (10.0) 
Number of patients who required intubation 1 (5.0) 
Admission to emergency room, Median (IQ), days  0 (0-0) 
Hospitalization, days 5.0 (3-6) 
Duration of oral tolerance during hospital administration, Median (IQ), days 3 (2-4) 
Duration of dyspnea situation, Median (IQ), days 1.5 (0.3-3) 
Number of patients who suffered from dyspnea 15 (75.0) 
Death 0 (0.0) 
Values were presented as median (interquartile, IQ), or numbers (percentages) 
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virus with SARS-CoV-2 (19), Interferon beta-1a 
was added to the antiviral combination treatment 
of patients.  SARS-CoV-2 enters the cell through 
interaction with host receptor Angiotensin-
Converting Enzyme 2 (ACE2), and then its positive 
stranded genome is released and its replication is 
initiated (19). The next steps of replication, 
transcription and translation lead to initiation of 
innate immune responses (11, 20). While the 
synthesis of Interferon, as a defensive mechanism 
of human, normally increases after a viral infection 
and this phenomenon can limit the viral infection, 
several studies have reported that Interferon 
production was limited after infection with SARS-
CoV (11, 20). Furthermore, several in-vitro studies 
reported that Interferon effectively restrains the 
replication of SARS-CoV, and this data indicate the 
efficacy of exogenous Interferon for treatment of 
SARS-CoV (8, 9, 11). Therefore, it seems that 
Interferon beta is one of the medications that can 
be used in combination with other antiviral drugs 
for management of Covid-19.  
Limitations 
Due to the Covid-19 pandemic and geopolitical 
situation of Iran, this study has several limitations. 
Firstly, only 20 patients were studied. A large 
number of patients were continually being 
admitted to Sina hospital, and due to the false 
negative results of PCR, we decided to consider 
other criteria for diagnosis of new corona virus 
infection. Secondly, based on the evidence available 
at the time and several updates in guidelines, 
patients did not receive the same standard 
treatment. Also, there was not a control group to 
compare the results with. To further investigate the 
effects of Interferon beta-1a in Covid-19, a two-
armed parallel trial has been designed and started 
by the same team (IRCT20150914024017N1). 
Conclusions 
Results of the current study are in favor of using 
Interferon beta-1a in addition to recommended 
antiviral treatment in Covid-19 patients. However, 
for confirming its efficacy and safety, two-armed 
randomized parallel clinical trials are needed. 
ACKNOWLEDGEMENTS 
We thank Seyed Hossein Seyedagha for assisting in 
statistical analysis of the data. Moreover, we would 
like to thank Dr. Arash Safaie and Dr. Mehrnoosh 
Aligholi-Zahraie for their contribution in data 
gathering. We also thank Mr. Rasoul Jahangiri for 
his assistance in patient care. The authors would 
also like to thank the statistics consultants of the 
Research Development Center of Sina Hospital for 
their technical assistance. 
AUTHORS’ CONTRIBUTION 
PP and MS conceptualized the paper. MA and SS 
analyzed the data, with input from AH, FN, SS, MP 
and HB. RR was involved with pharmacological 
advice and design of the study. PP wrote the initial 
draft with all authors providing critical feedback 
and edits to subsequent revisions. All authors 
approved the final draft of the manuscript. MS was 
the guarantor. All authors agree to be accountable 
for all aspects of the work and will ensure that 
questions related to the accuracy or integrity of any 
part of the work are appropriately investigated and 
resolved. 
CONFLICT OF INTEREST 
Dr. Morteza Azhdarzadeh is an employee of the 
CinnaGen co. and has no other conflict of interest. 
All other authors have no conflict of interest to 
declare.  
FUNDING 
The study was funded by a grant received from Vice 
Chancellor for Research, Tehran University of 
Medical Sciences. All the medications used in this 
trial were provided by CinnaGen Co. free of charge.
REFERENCES 
1. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. Brief Report: First Case of 2019 
Novel Coronavirus in the United States. N Engl J Med. 2020;382(10):929-36. 
2. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 
in China. N Engl J Med. 2020;382(18):1708-20. 
3. World Health Organization. Coronavirus disease (COVID-2019) situation reports: WHO; 2020 [Available 
from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/]. 
4. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized 
with Severe Covid-19. N Engl J Med. 2020;382(19):1787-99. 
ADVANCED JOURNAL OF EMERGENCY MEDICINE. 2020;4(2s):e51 Payandemehr et al 
   
 
6 Copyright © 2020 Tehran University of Medical Sciences  
This open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 License (CC BY-NC 4.0). 
 
5. Rubin EJ, Baden LR, Morrissey S. Audio Interview: New Research on Possible Treatments for Covid-19. 
N Engl J Med. 2020;382(12):e30. 
6. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients with COVID-19 
with convalescent plasma. JAMA. 2020;323(16):1582-9. 
7. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 viral load in upper respiratory 
specimens of infected patients. N Engl J Med. 2020;382(12):1177-9. 
8. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr H. Treatment of SARS with human 
interferons. Lancet. 2003;362(9380):293-4. 
9. Haagmans BL, Kuiken T, Martina BE, Fouchier RA, Rimmelzwaan GF, Van Amerongen G, et al. Pegylated 
interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nature Med. 
2004;10(3):290-3. 
10. Hensley LE, Fritz EA, Jahrling PB, Karp C, Huggins JW, Geisbert TW. Interferon-β 1a and SARS 
coronavirus replication. Emerg Infect Dis. 2004;10(2):317. 
11. Haagmans BL, Osterhaus AD. Coronaviruses and their therapy. Antiviral Res. 2006;71(2-3):397-403. 
12. Kindler E, Thiel V, Weber F. Interaction of SARS and MERS coronaviruses with the antiviral interferon 
response.  Advances in virus research. 96: Elsevier; 2016. p. 219-43. 
13. Widagdo W, Okba NM, Raj VS, Haagmans BL. MERS-coronavirus: From discovery to intervention. One 
Health. 2017;3:11-6. 
14. Morgenstern B, Michaelis M, Baer PC, Doerr HW, Cinatl Jr J. Ribavirin and interferon-β synergistically 
inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Biophys Res 
Commun. 2005;326(4):905-8. 
15. Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of 
remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 
2020;11(1):1-14. 
16. Talebpour M, Hadadi A, Oraii A, Ashraf H. Rationale and Design of a Registry in a Referral and 
Educational Medical Center in Tehran, Iran: Sina Hospital Covid-19 Registry (SHCo-19R). Adv J Emerg Med. 
2020; In press. 
17. Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA, Zhang N, et al. Chest CT findings in coronavirus disease-
19 (COVID-19): relationship to duration of infection. Radiology. 2020:200463. 
18. Cheng PN, Marcellin P, Bacon B, Farrell G, Parsons I, Wee T, et al. Racial differences in responses to 
interferon‐β‐1a in chronic hepatitis C unresponsive to interferon‐α: a better response in Chinese patients. 
Journal of viral hepatitis. 2004;11(5):418-26. 
19. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: 
an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94(7):e00127-20. 
20. Cheung CY, Poon LL, Ng IH, Luk W, Sia S-F, Wu MH, et al. Cytokine responses in severe acute respiratory 
syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis. J Virol. 
2005;79(12):7819-26. 
 
